American pharma industry spends record amount lobbying Washington

23 January 2018

A lobbying disclosure form filed by The Pharmaceutical Research and Manufacturers of America (PhRMA) reveals the leading industry trade body spent about a third more lobbying Washington DC last year, compared with 2016.

The group spent $25.4 million during President Trump’s first year in office, compared with $20 million the year before. In 2014, PhRMA spent $16.5 million on lobbying.

Much of the increase has been attributed to hardened rhetoric from the incoming administration at the start of the year around drug pricing and practices in the industry.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK